PRKCA and diabetes mellitus: A recent study showed how treatment with Neuregulin1 (NRG-1) was able to rescue titin-based cardiomyocyte stiffening in diabetic mouse hearts (Hopf et al., 2018), via increased PKG and ERK1/2 activity and reduced PKCα activity, which reversed the changes in titin-phosphorylation associated with diabetes.